Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 8/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.45 |
| ▸ | ITGAV | P06756 | 4/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790371 | 0.85 | HCRTR1 (0.47) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3390604 | 0.85 | HCRTR1 (0.47) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL291756 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP3A4GRIN2BCYP2D6 | |
| SCHEMBL13309233 | 0.83 | HCRTR1 (0.43) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL19256481 | 0.77 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL29560568 | 0.77 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL13232073 | 0.76 | POLB (0.46) | — | |
| SCHEMBL7910556 | 0.76 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL3385637 | 0.76 | CYP3A4 (0.50) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3385643 | 0.76 | HCRTR1 (0.57) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133908-B2 | Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine | GLAXO GROUP LIMITED (GB) | 2012-03-13 | — | — | US | disclosed |
| US-8133908-B2 | Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine | GLAXO GROUP LIMITED (GB) | 2012-03-13 | — | — | US | disclosed |
| US-20100168131-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
| WO-2010063662-A1 | N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0] HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168131-A1 | NOVEL COMPOUNDS | HTR3B, HNMT, TPMT | ITGB1 997/4885ITGA5 1098/4885ITGB3 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.